The company develops innovative therapies that improve patient outcomes and adherence, including oral and injectable solutions
Noted side effects of GLP-1 receptor agonists include: nausea, vomiting, constipation, diarrhea, or abdominal pain that can subside with continued use
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
Side effect profiles shift depending on when you inject
The company has not said when it plans to launch in China, indicated potential pricing or given details on the volume of supplies it would dedicate to the worlds second largest country
As of December 2023, the legal landscape is evolving